Copyright
©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1468-1480
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Clinical endpoint | |
Complete response | 1 (1) |
Partial response | 26 (25) |
Overall response | 27 (26) |
Stable disease | 28 (26) |
Disease control rate | 55 (52) |
Progressive disease | 52 (48) |
- Citation: Fasano M, Pirozzi M, Vitale P, Damiano V, Ronzino G, Farese S, Carfora V, Ciccarelli G, Di Giovanni I, Facchini S, Cennamo G, Caraglia M, Ciardiello F, Addeo R. Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study. World J Clin Oncol 2024; 15(12): 1468-1480
- URL: https://www.wjgnet.com/2218-4333/full/v15/i12/1468.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i12.1468